Elicera Therapeutics AB (OSTO:ELIC) EV-to-Revenue : (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Elicera Therapeutics AB's enterprise value is kr4.17 Mil. Elicera Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00 Mil. Therefore, Elicera Therapeutics AB's EV-to-Revenue for today is .

The historical rank and industry rank for Elicera Therapeutics AB's EV-to-Revenue or its related term are showing as below:

OSTO:ELIC's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.12
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-23), Elicera Therapeutics AB's stock price is kr0.956. Elicera Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00. Therefore, Elicera Therapeutics AB's PS Ratio for today is .

Elicera Therapeutics AB EV-to-Revenue Historical Data

The historical data trend for Elicera Therapeutics AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB EV-to-Revenue Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

46,912.64

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Elicera Therapeutics AB's EV-to-Revenue

For the Biotechnology subindustry, Elicera Therapeutics AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's EV-to-Revenue falls into.

Elicera Therapeutics AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Elicera Therapeutics AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	4.166	/	0
	=

Elicera Therapeutics AB's current Enterprise Value is kr4.17 Mil.
Elicera Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Elicera Therapeutics AB (OSTO:ELIC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Elicera Therapeutics AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.956	/	0
	=

Elicera Therapeutics AB's share price for today is kr0.956.
Elicera Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

Elicera Therapeutics AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines